Trial
NCT02348359
X-82 to Treat Age-related Macular Degeneration
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Tyrogenex
Collaborators
SynteractHCR; International Drug Development Institute
Condition
Age-Related Macular Degeneration (AMD)
Intervention
X-82
Why stopped
Interim analysis found study had achieved primary objective
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-02-11